Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

NCT04009668 is registered in ClinicalTrials.gov with University of Michigan as lead sponsor.

NCT NCT04009668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04009668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Lead sponsor
University of Michigan
Phase
Phase 2
Overall status
Completed
Start date
October 2, 2019
Completion date
October 3, 2023
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis, fsgs, mcd, minimal change disease